FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Private Issuer
Pursuant to Rule 13s - 16 or 15d - 16 of
the Securities Exchange Act of 1934
For the month of October, 2006
Acambis plc
(Translation of registrant's name into English)
Peterhouse Technology Park
100 Fulbourn Road
Cambridge CB1 9PT
England
(address of principal executive offices)
(Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F
Forms 20-F X Form 40-F
Indicate by check mark whether the registrant by furnishing the information
contained in this Form also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934).
Yes No X
(if "Yes" is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g3-2(b): 82- ).
Enclosure: No.1 Holding(s) in Company announcement made on 02 October, 2006
No.2 Director/PDMR Shareholding announcement made on 05 October,2006
No.3 Directors' interests in share announcement made on
05 October, 2006
No.4 Director/PDMR Shareholding announcement made on 20 October,2006
No.5 Holding(s) in Company announcement made on 20 October, 2006
Enclosure: No.1
Holding in Company
Cambridge, UK and Cambridge, Massachusetts - 2 October 2006 - Acambis plc
("Acambis") (LSE: ACM, NASDAQ: ACAM) announces an interest in its shares by The
Goldman Sachs Group, Inc.
On 29 September 2006, Acambis received notification that, as of the close of
business on 27 September 2006, The Goldman Sachs Group, Inc., ("GS Inc") of 85
Broad Street, New York, NY 10004, USA, was interested in a total of 9,648,576
ordinary shares of 10p each, representing an 8.99% holding of Acambis' issued
share capital.
Of these 9,648,576 shares:
a) the interest in 263,095 shares arose from an interest held
by Goldman, Sachs & Co. ("GS&Co."), a direct subsidiary of GS Inc., acting as
custodian; these shares are, or will be, registered in the name of Goldman Sachs
Securities (Nominees), Limited ("GSSN");
b) the interest in 3,300 shares arose from an interest held by
GS&Co, a direct subsidiary of GS Inc, acting as a discretionary manager. These
shares are, or will be, registered in the name of GSSN;
c) the interest in 334,700 shares arose from an interest held
by GS&Co, acting as custodian of 167,350 American Depositary Receipts ("ADRs");
these ADRs are, or will be, held at The Depositary Trust Company, New York;
d) the interest in 9,047,481 shares arose from a beneficial
interest held by Goldman Sachs International, a direct subsidiary of GS Inc;
these shares are, or will be, registered at CREST in account CREPTEMP.
-ends-
Enquiries:
Acambis plc
Elizabeth Brown, Company Secretary:
Tel: +44 (0) 1223 275 300
Lyndsay Wright, VP, Communications and Investor Relations:
Tel: +44 (0) 1223 275 300
About Acambis
Acambis is a leading developer of vaccines to prevent and treat infectious
diseases. Recognised internationally as the leading producer of smallpox
vaccines, Acambis is developing an investigational smallpox vaccine, ACAM2000,
and is manufacturing emergency-use stockpiles of this investigational vaccine
for the US Government and other governments around the world. It is also
developing an attenuated smallpox vaccine, MVA3000, under contracts with the US
National Institutes of Health. Acambis' investigational vaccine against Japanese
encephalitis, ChimeriVax-JE, is undergoing Phase 3 clinical testing. It also has
the most advanced investigational vaccine against the West Nile virus, which has
spread to 48 US States in the last seven years, and a vaccine against
Clostridium difficile bacteria, a leading cause of hospital-acquired infections.
Acambis is based in Cambridge, UK and Cambridge, Massachusetts, US. Its primary
listing is on the London Stock Exchange (ACM) and its shares are listed in the
form of American Depositary Receipts on NASDAQ (ACAM). More information is
available at www.acambis.com.
"Safe Harbor" statement under the Private Securities Litigation Reform Act of
1995:
The statements in this news release that are not historical facts are
forward-looking statements that involve risks and uncertainties, including the
timing and results of clinical trials, product development, manufacturing and
commercialisation risks, the risks of satisfying the regulatory approval process
in a timely manner, the need for and the availability of additional capital. For
a discussion of these and other risks and uncertainties see "Risk management" in
the Company's 2005 Annual Report and "Risk factors" in its Form 20-F, in
addition to those detailed on the Company's website and in the Company's filings
made with the Securities and Exchange Commission from time to time. These
forward-looking statements are based on estimates and assumptions made by the
management of Acambis and are believed to be reasonable, though are inherently
uncertain and difficult to predict. Actual results or experience could differ
materially from the forward-looking statements.
Enclosure: No.2
Increase in Director's shareholding
Cambridge, UK - 5 October 2006 - Acambis plc ("Acambis") (LSE: ACM, NASDAQ:
ACAM) announces that on 4 October 2006, David Lawrence, Chief Financial Officer,
purchased a total of 1,600 shares at 169.8p per share for himself and on behalf
of certain family members. After this transaction, the shareholding in Acambis
held by Mr Lawrence and on behalf of his family (being connected persons) was
9,900 shares, representing approximately 0.01% of Acambis' issued share capital.
Enquiries:
Acambis plc
Elizabeth Brown, Company Secretary Tel: +44 (0) 1223 275 300
Lyndsay Wright, VP, Communications and Investor
Relations
-ends-
About Acambis
Acambis is a leading developer of vaccines to prevent and treat infectious
diseases. Recognised internationally as the leading producer of smallpox
vaccines, Acambis is developing an investigational smallpox vaccine, ACAM2000,
and is manufacturing emergency-use stockpiles of this investigational vaccine
for the US Government and other governments around the world. It is also
developing an attenuated smallpox vaccine, MVA3000, under contracts with the US
National Institutes of Health. Acambis' investigational vaccine against Japanese
encephalitis, ChimeriVax-JE, is undergoing Phase 3 clinical testing. It also has
the most advanced investigational vaccine against the West Nile virus, which has
spread to 48 US States in the last seven years, and a vaccine against
Clostridium difficile bacteria, a leading cause of hospital-acquired infections.
Acambis is based in Cambridge, UK and Cambridge, Massachusetts, US, and is
listed on the London Stock Exchange (ACM). More information is available at
www.acambis.com.
"Safe Harbor" statement under the Private Securities Litigation Reform Act of
1995:
The statements in this news release that are not historical facts are
forward-looking statements that involve risks and uncertainties, including the
timing and results of clinical trials, product development, manufacturing and
commercialisation risks, the risks of satisfying the regulatory approval process
in a timely manner, the need for and the availability of additional capital. For
a discussion of these and other risks and uncertainties see "Risk management" in
the Company's 2005 Annual Report and "Risk factors" in its Form 20-F, in
addition to those detailed on the Company's website and in the Company's filings
made with the Securities and Exchange Commission from time to time. These
forward-looking statements are based on estimates and assumptions made by the
management of Acambis and are believed to be reasonable, though are inherently
uncertain and difficult to predict. Actual results or experience could differ
materially from the forward-looking statements.
Enclosure: No.3
Directors' interests in shares
Cambridge, UK - 5 October 2006 - Acambis plc ("Acambis") (LSE: ACM, NASDAQ:
ACAM) announces that, on 3 October 2006, the following grants of options under
the Acambis 2006 Unapproved Share Option Plan were made to the two Executive
Directors:
Total shares over which
Director Share options options held (note 1)
Gordon Cameron 233,225 1,184,521
David Lawrence 127,096 575,726
The share options were granted over ordinary 10p shares at an exercise price of
155p per share and are exercisable between 3 October 2009 and 2 October 2016. No
amount was payable by the Directors on the grant of these share options.
Note 1: The total shares over which options (share options and long-term
incentive awards) are held following the transactions detailed within this news
release.
Enquiries:
Acambis plc
Elizabeth Brown, Company Secretary Tel: +44 (0) 1223 275 300
Lyndsay Wright, VP, Communications and Investor
Relations
-ends-
About Acambis
Acambis is a leading developer of vaccines to prevent and treat infectious
diseases. Recognised internationally as the leading producer of smallpox
vaccines, Acambis is developing an investigational smallpox vaccine, ACAM2000,
and is manufacturing emergency-use stockpiles of this investigational vaccine
for the US Government and other governments around the world. It is also
developing an attenuated smallpox vaccine, MVA3000, under contracts with the US
National Institutes of Health. Acambis' investigational vaccine against Japanese
encephalitis, ChimeriVax-JE, is undergoing Phase 3 clinical testing. It also has
the most advanced investigational vaccine against the West Nile virus, which has
spread to 48 US States in the last seven years, and a vaccine against
Clostridium difficile bacteria, a leading cause of hospital-acquired infections.
Acambis is based in Cambridge, UK and Cambridge, Massachusetts, US, and is
listed on the London Stock Exchange (ACM). More information is available at
www.acambis.com.
"Safe Harbor" statement under the Private Securities Litigation Reform Act of
1995:
The statements in this news release that are not historical facts are
forward-looking statements that involve risks and uncertainties, including the
timing and results of clinical trials, product development, manufacturing and
commercialisation risks, the risks of satisfying the regulatory approval process
in a timely manner, the need for and the availability of additional capital. For
a discussion of these and other risks and uncertainties see "Risk management" in
the Company's 2005 Annual Report and "Risk factors" in its Form 20-F, in
addition to those detailed on the Company's website and in the Company's filings
made with the Securities and Exchange Commission from time to time. These
forward-looking statements are based on estimates and assumptions made by the
management of Acambis and are believed to be reasonable, though are inherently
uncertain and difficult to predict. Actual results or experience could differ
materially from the forward-looking statements.
Enclosure: No.4
Directors' interests in shares
Cambridge, UK and Cambridge, Massachusetts - 20 October 2006 - Acambis plc
("Acambis") (LSE: ACM, NASDAQ: ACAM) announces that, on 12 October 2006, the
following grants of options under the Acambis 1995 Savings-Related Share Option
Scheme were made to two Executive Directors:
Total shares over which
Director Share options options held (note 1)
Gordon Cameron 8,008 1,187,878
David Lawrence 8,008 579,083
The share options were granted over ordinary 10p shares at an exercise price of
118p per share. The exercise periods applicable are 1 December 2009 to 1 June
2010. No amount was payable by the Directors on the grant of these share
options.
Note 1: The total shares over which options are held (share options and
long-term incentive awards) following the above transactions detailed within
this news release.
Enquiries:
Acambis plc
Elizabeth Brown, Company Secretary Tel: +44 (0) 1223 275 300
-ends-
About Acambis
Acambis is a leading biotechnology company targeting infectious diseases with
novel vaccines. Acambis' development-stage pipeline includes vaccines that could
either offer improvements over existing products or target unmet medical needs.
Its investigational vaccine against Japanese encephalitis, ChimeriVax-JE, which
is undergoing Phase 3 clinical testing, is intended to provide an "ideal"
vaccine to address the estimated 50,000 cases of this viral disease in Asia
every year. Acambis' proprietary ChimeriVax technology, developed in association
with St Louis University, has also been used to develop ChimeriVax-West Nile,
which is undergoing Phase 2 clinical testing, making it the most advanced
investigational vaccine against the West Nile virus. Acambis also has the only
vaccine in development against Clostridium difficile bacteria, a leading cause
of hospital-acquired infections. Recognised internationally as the leading
producer of smallpox vaccines, Acambis is developing an investigational smallpox
vaccine, ACAM2000, and is manufacturing emergency-use stockpiles of this
investigational vaccine for the US Government and other governments around the
world. It is also developing an attenuated smallpox vaccine, MVA3000, under
contracts with the US National Institutes of Health.
Acambis is based in Cambridge, UK and Cambridge, Massachusetts, US, and is
listed on the London Stock Exchange (ACM). Its shares are listed on NASDAQ
(ACAM) in the form of American Depositary Receipts. More information is
available at www.acambis.com.
"Safe Harbor" statement under the Private Securities Litigation Reform Act of
1995:
The statements in this news release that are not historical facts are
forward-looking statements that involve risks and uncertainties, including the
timing and results of clinical trials, product development, manufacturing and
commercialisation risks, the risks of satisfying the regulatory approval process
in a timely manner, the need for and the availability of additional capital. For
a discussion of these and other risks and uncertainties see "Risk management" in
the Company's 2005 Annual Report and "Risk factors" in its Form 20-F, in
addition to those detailed on the Company's website and in the Company's filings
made with the Securities and Exchange Commission from time to time. These
forward-looking statements are based on estimates and assumptions made by the
management of Acambis and are believed to be reasonable, though are inherently
uncertain and difficult to predict. Actual results or experience could differ
materially from the forward-looking statements.
Enclosure No.5
Holding in Company
Cambridge, UK and Cambridge, Massachusetts - 20 October 2006 - Acambis plc
("Acambis") (LSE: ACM, NASDAQ: ACAM) announces an interest in its shares by The
Goldman Sachs Group, Inc.
On 19 September 2006, Acambis received notification that, as of the close of
business on 17 October 2006, The Goldman Sachs Group, Inc., ("GS Inc") of 85
Broad Street, New York, NY 10004, USA, was interested in a total of 9,672,938
ordinary shares of 10p each, representing an 9.01% holding of Acambis' issued
share capital.
Of these 9,672,938 shares:
a) the interest in 461,765 shares arose from an interest held by Goldman,
Sachs & Co. ("GS&Co."), a direct subsidiary of GS Inc., acting as
custodian; these shares are, or will be, registered in the name of Goldman
Sachs Securities (Nominees), Limited ("GSSN");
b) the interest in 3,300 shares arose from an interest held by GS&Co, a direct
subsidiary of GS Inc, acting as a discretionary manager. These shares are,
or will be, registered in the name of GSSN;
c) the interest in 334,700 shares arose from an interest held by GS&Co, acting
as custodian of 167,350 American Depositary Receipts ("ADRs"); these ADRs
are, or will be, held at The Depositary Trust Company, New York;
d) the interest in 8,873,173 shares arose from a beneficial interest held by
Goldman Sachs International, a direct subsidiary of GS Inc; these shares
are, or will be, registered at CREST in account CREPTEMP.
-ends-
Enquiries:
Acambis plc
Elizabeth Brown, Company Secretary: Tel: +44 (0) 1223 275 300
Lyndsay Wright, VP, Communications and Investor Relations:
Tel: +44 (0) 1223 275 300
About Acambis
Acambis is a leading developer of vaccines to prevent and treat infectious
diseases. Recognised internationally as the leading producer of smallpox
vaccines, Acambis is developing an investigational smallpox vaccine, ACAM2000,
and is manufacturing emergency-use stockpiles of this investigational vaccine
for the US Government and other governments around the world. It is also
developing an attenuated smallpox vaccine, MVA3000, under contracts with the US
National Institutes of Health. Acambis' investigational vaccine against Japanese
encephalitis, ChimeriVax-JE, is undergoing Phase 3 clinical testing. It also has
the most advanced investigational vaccine against the West Nile virus, which has
spread to 48 US States in the last seven years, and a vaccine against
Clostridium difficile bacteria, a leading cause of hospital-acquired infections.
Acambis is based in Cambridge, UK and Cambridge, Massachusetts, US. Its primary
listing is on the London Stock Exchange (ACM) and its shares are listed in the
form of American Depositary Receipts on NASDAQ (ACAM). More information is
available at www.acambis.com.
"Safe Harbor" statement under the Private Securities Litigation Reform Act of
1995:
The statements in this news release that are not historical facts are
forward-looking statements that involve risks and uncertainties, including the
timing and results of clinical trials, product development, manufacturing and
commercialisation risks, the risks of satisfying the regulatory approval process
in a timely manner, the need for and the availability of additional capital. For
a discussion of these and other risks and uncertainties see "Risk management" in
the Company's 2005 Annual Report and "Risk factors" in its Form 20-F, in
addition to those detailed on the Company's website and in the Company's filings
made with the Securities and Exchange Commission from time to time. These
forward-looking statements are based on estimates and assumptions made by the
management of Acambis and are believed to be reasonable, though are inherently
uncertain and difficult to predict. Actual results or experience could differ
materially from the forward-looking statements.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant Peptide Therapeutics Group has duly caused this report to be
signed on its behalf by the undersigned, thereunto duly authorized.
Date: 31st October, 2006 ACAMBIS PLC
By: /s/ Lyndsay Wright
Name: Lyndsay Wright
Title: VP, Communications and IR.